Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in immune-mediated inflammatory diseases.
Findings demonstrate that IL-2LD not only expands and activates Treg cells but also shapes an anti-inflammatory transcriptomic landscape characterised by ISG downregulation in Treg and Tconv cells.